American Association for Cancer Research
Browse
00085472can092422-sup-can_11-1-09_turk.pdf (312.79 kB)

Supplementary Figures 1-3, Tables 1-3 from Identification of Compounds Selectively Killing Multidrug-Resistant Cancer Cells

Download (312.79 kB)
journal contribution
posted on 2023-03-30, 19:30 authored by Dóra Türk, Matthew D. Hall, Benjamin F. Chu, Joseph A. Ludwig, Henry M. Fales, Michael M. Gottesman, Gergely Szakács
Supplementary Figures 1-3, Tables 1-3 from Identification of Compounds Selectively Killing Multidrug-Resistant Cancer Cells

History

ARTICLE ABSTRACT

There is a great need for the development of novel chemotherapeutic agents that overcome the emergence of multidrug resistance (MDR) in cancer. We catalogued the National Cancer Institute's DTP drug repository in search of compounds showing increased toxicity in MDR cells. By comparing the sensitivity of parental cell lines with MDR derivatives, we identified 22 compounds possessing MDR-selective activity. Analysis of structural congeners led to the identification of 15 additional drugs showing increased toxicity in Pgp-expressing cells. Analysis of MDR-selective compounds led to the formulation of structure activity relationships and pharmacophore models. This data mining coupled with experimental data points to a possible mechanism of action linked to metal chelation. Taken together, the discovery of the MDR-selective compound set shows the robustness of the developing field of MDR-targeting therapy as a new strategy for resolving Pgp-mediated MDR. [Cancer Res 2009;69(21):8293–301]

Usage metrics

    Cancer Research

    Licence

    Exports